Pipeline catalysts in 2H 2026 (SURF302 Aug, BEACH301 Q4) are key events. Near-term stock move hinges on clinical data, not financials. Monitor enrollment updates and early efficacy signals.
Price Chart
Executive Summary
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R&D spending. Cash and investments stood at $383.5M following a $147.9M ATM raise, extending runway into 2H 2028. Pipeline advancements include first patient dosed in potentially registrational SURF303 study and dose escalation cleared in BEACH301.
Key Financial Metrics
Key Facts
- Q1 2026 net loss per share -$0.64 vs -$0.47 in Q1 2025
- Cash and marketable securities of $383.5M; runway into 2H 2028
- Received $147.9M net proceeds from ATM offering (4,690,532 shares)
- First patient dosed in Phase 2a/b SURF303 study for LG-UTUC; initial results 2027
- SURF302 initial three-month complete response data expected August 2026 (n>20 enrolled)
- BEACH301 cleared fourth dose level; safety sentinel cohort results expected Q4 2026
Financial Impact
Net loss widened by 40% YoY; cash position strengthened by $147.9M ATM raise
Risk Factors
- Clinical trial failure or disappointing data in upcoming readouts
- Dilution from ATM offering (4.7M shares) may pressure stock
- Cash burn rate increasing with expanded clinical programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220638 |
| Document: tyra-20260513.htm | 0001193125-26-220638 |
| Document: 0001193125-26-220638-index-headers.html | 0001193125-26-220638 |
| Document: 0001193125-26-220638-index.html | 0001193125-26-220638 |
| Document: 0001193125-26-220638.txt | 0001193125-26-220638 |
| 8-K Data (Synthetic) | 0001193125-26-220638 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | S-3ASR | $25.07 $25.65 | ▲ +2.31% | ▲ +2.21% | $20.50 (−18.21%) |
Sep 9, 2026 23d ago | 8-K | $22.01 $24.35 | ▲ +10.63% | ▲ +11.73% | $20.50 (−6.84%) |
Aug 4, 2026 8w ago | 424B5 | $25.71 $25.30 | ▲ +1.59% | ▲ +1.95% | $20.50 (+20.25%) |
Jun 26, 2026 13w ago | 144 | $32.11 $30.86 | ▲ +3.89% | ▲ +5.28% | $20.50 (+36.14%) |
May 13, 2026 20w ago | 8-K | $36.19 $33.78 | ▼ −6.66% | ▼ −5.50% | $20.50 (−43.34%) |
Apr 20, 2026 23w ago | 3 | $36.69 $35.06 | ▼ −4.44% | ▼ −5.53% | $20.50 (−44.11%) |
Apr 17, 2026 24w ago | DEFA14A | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 17, 2026 24w ago | 8-K | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 13, 2026 24w ago | 144 | $35.27 $36.69 | ▲ +4.03% | ▲ +2.63% | $20.50 (−41.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access